PARIS--(BUSINESS WIRE)--Ipsen (Paris:IPN) today announced the European Medicines Agency (EMEA) has validated its application to market febuxostat in the European Union (EU), for the management of symptomatic hyperuricaemia. Further to the development and marketing agreement signed in July 2003 between Ipsen and Teijin, holder of the product’s rights, Ipsen was endorsed to develop and market febuxostat in Europe.
